Accessible and Robust High-Throughput Western Blotting for Small Sample Sizes
Accessible and Robust High-Throughput Western Blotting for Small Sample Sizes
批准号:
10545990
负责人:
Marc R. Birtwistle
金额:
$28.88万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-22 至 2024-09-21
关键词:
AddressAntibodiesBiological AssayBiologyBiomedical ResearchCapillary ElectrophoresisCapitalCollaborationsCoomassie blueDevicesElectrophoresisFamiliarityFluorescenceGelGoalsGoldHandImmunoprecipitationInterventionKnowledgeLettersLiceMeasurementMembraneMethodsMolecular WeightOutcomePainPharmacologic SubstancePhasePost-Translational Protein ProcessingPreparationProcessProtein AnalysisProteinsProtocols documentationPublicationsRefractoryResearchRobotRoboticsRunningSample SizeSamplingShippingShipsSignal TransductionSmall Business Technology Transfer ResearchSourceSpecificityTechniquesTechnologyTestingTimeTrustWestern BlottingWidthbasecommercial applicationcostdesigninnovationinterestnoveloperationpolyacrylamide gelspre-clinicalresearch and developmentscale upsuccesstechnological innovation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The goal of this Phase I STTR is for Blotting Innovations, LLC to establish feasibility of a commercializable
mesowestern—a high-throughput, affordable western blotting technique that we recently developed.
Western blotting is a technique for molecular-weight-resolved analysis of proteins and their post-translational
modifications that is practiced today almost identically to when it was first introduced in the late 1970s. It remains
one of the most widely-used protein assays across biomedical research, perhaps the most used in the past 10
years. Major reasons are that it is low-cost, often a gold standard, and well-established in most labs. Yet, western
blotting has been refractory to scale up, typically limited to ~10 samples per run. Capillary electrophoresis-based
separation in automated apparati has been developed that increase throughput with smaller samples, but are
expensive and can be sensitive to sample preparation. The microwestern uses piezoelectric pipetting for up to
96 blots at a time in a standard footprint; however, the piezoelectric apparatus imposes capital cost and technical
difficultly deterrents. We established the mesowestern that analyzes over 300 samples with a similar footprint,
affordability, and ease-of-use as traditional western blots, and with ~10-fold lower sample size requirements.
Our main products are a precast mesowestern gel that is loadable by a low-cost pipetting robot (opentrons) and
a novel yet affordable tank for immersed horizontal electrophoresis of the loaded precast gel. A main innovation
is a customizable gel casting device that produces polyacrylamide gels with hundreds of ~1 uL wells, and
associated protocols for robust gel casting and electrophoresis. Another main innovation is immersed horizontal
tank electrophoresis for polyacrylimide gels; only semi-dry horizontal (microwestern) or immersed vertical tank
(traditional) are currently available. Phase I Hypothesis. Can precast mesowestern gels be robustly-loaded
robotically, and then subjected to immersed horizontal tank electrophoresis? We hypothesize that this can be
accomplished by designing a rigid insert that holds the gel during casting and shipping but also fits into (i)
opentrons pipetting robots and (ii) a low-cost, horizontal immersed electrophoresis apparatus. We have two Aims
that will establish feasibility of the product by testing this hypothesis. In Aim 1, we will establish robust robotic
loading of shipped, precast mesowestern gels. We focus on Opentrons micropipetting robots that are easy to
use and very affordable. In Aim 2, we will establish robust electrophoresis of robotically-loaded mesowestern
gels. Success in each aim is defined by variability (CV%) across analytes and technicians to be <10%. We
expect to have a beta-testable product at the end of Phase I. Phase II would focus on expanding to different
sample types (e.g. Immunoprecipitation-western) and across antibodies, as well as on robust transfer to
membrane (another main variability source). Our market is academic research labs and pre-clinical
pharmaceutical R&D labs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gelbrane: Combined Gel and Membrane for Robust Western Blotting
-
批准号:10759072
-
项目类别:
-
资助金额:$29.77万
-
财政年份:2023
-
负责人:Marc R. Birtwistle
-
依托单位:
Mechanistic Pharmacodynamic Modeling for Drug Combination Responses
-
批准号:10398952
-
项目类别:
-
资助金额:$37.23万
-
财政年份:2021
-
负责人:Marc R. Birtwistle
-
依托单位:
Mechanistic Pharmacodynamic Modeling for Drug Combination Responses
-
批准号:10580895
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2021
-
负责人:Marc R. Birtwistle
-
依托单位:
Mechanistic Pharmacodynamic Modeling for Drug Combination Responses
-
批准号:10592423
-
项目类别:
-
资助金额:$37.23万
-
财政年份:2021
-
负责人:Marc R. Birtwistle
-
依托单位:
Mechanistic Pharmacodynamic Modeling for Drug Combination Responses
-
批准号:10206849
-
项目类别:
-
资助金额:$37.23万
-
财政年份:2021
-
负责人:Marc R. Birtwistle
-
依托单位:
Administrative Supplement to Support Summer Undergraduate Research for the Parent MIRA Award R35 GM141891 “Mechanistic Pharmacodynamic Modeling for Drug Combinations"
-
批准号:10809119
-
项目类别:
-
资助金额:$0.99万
-
财政年份:2021
-
负责人:Marc R. Birtwistle
-
依托单位:
Multiplexed, Quantitative Fluorescence Imaging in Tumor Sections
-
批准号:9566479
-
项目类别:
-
资助金额:$19.85万
-
财政年份:2015
-
负责人:Marc R. Birtwistle
-
依托单位:
Multiplexed, Quantitative Fluorescence Imaging in Tumor Sections
-
批准号:9329290
-
项目类别:
-
资助金额:$22.12万
-
财政年份:2015
-
负责人:Marc R. Birtwistle
-
依托单位:
Multiplexed, Quantitative Fluorescence Imaging in Tumor Sections
-
批准号:8928922
-
项目类别:
-
资助金额:$25.81万
-
财政年份:2015
-
负责人:Marc R. Birtwistle
-
依托单位:
Drug Combination Signatures for Prediction and Mitigation of Toxicity
-
批准号:8787833
-
项目类别:
-
资助金额:$209.97万
-
财政年份:2014
-
负责人:Marc R. Birtwistle
-
依托单位:
Predicting the Heterogeneity of Cell-Fate Decisions
-
批准号:9027234
-
项目类别:
-
资助金额:$7.72万
-
财政年份:2014
-
负责人:Marc R. Birtwistle
-
依托单位:
Predicting the Heterogeneity of Cell-Fate Decisions
-
批准号:9199219
-
项目类别:
-
资助金额:$18.86万
-
财政年份:2014
-
负责人:Marc R. Birtwistle
-
依托单位:
Predicting the Heterogeneity of Cell-Fate Decisions
-
批准号:8631470
-
项目类别:
-
资助金额:$34.86万
-
财政年份:2014
-
负责人:Marc R. Birtwistle
-
依托单位:
Predicting the Heterogeneity of Cell-Fate Decisions
-
批准号:8806562
-
项目类别:
-
资助金额:$33.48万
-
财政年份:2014
-
负责人:Marc R. Birtwistle
-
依托单位:
Project 1 (Birtwistle)
-
批准号:8720327
-
项目类别:
-
资助金额:$9.41万
-
财政年份:2007
-
负责人:Marc R. Birtwistle
-
依托单位:
Project 1 (Birtwistle)
-
批准号:8728886
-
项目类别:
-
资助金额:$8.47万
-
财政年份:2007
-
负责人:Marc R. Birtwistle
-
依托单位:
Project 1 (Birtwistle)
-
批准号:8916135
-
项目类别:
-
资助金额:$9.41万
-
财政年份:2007
-
负责人:Marc R. Birtwistle
-
依托单位:
Project 1 (Birtwistle)
-
批准号:9335913
-
项目类别:
-
资助金额:$9.41万
-
财政年份:2007
-
负责人:Marc R. Birtwistle
-
依托单位:
Administrative Core
-
批准号:9540045
-
项目类别:
-
资助金额:$19.81万
-
财政年份:--
-
负责人:Marc R. Birtwistle
-
依托单位:
Data Generation Core
-
批准号:9320878
-
项目类别:
-
资助金额:$92.15万
-
财政年份:--
-
负责人:Marc R. Birtwistle
-
依托单位:
海外基金